Abstract
In randomized controlled trials, maintenance treatment for relapse prevention has been proven to be efficacious in patients responding in acute treatment, its efficacy in long-term outcome in “real-world patients” has yet to be proven. Three-year long-term data from a large naturalistic multisite follow-up were presented. Severe relapse was defined as suicide, severe suicide attempt, or rehospitalization. Next to relapse rates, possible risk factors including antidepressant medication were identified using univariate generalized log-rank tests and multivariate Cox proportional hazards model for time to severe relapse. Overall data of 458 patients were available for analysis. Of all patients, 155 (33.6 %) experienced at least one severe relapse during the 3-year follow-up. The following variables were associated with a shorter time to a severe relapse in univariate and multivariate analyses: multiple hospitalizations, presence of avoidant personality disorder, continuing antipsychotic medication, and no further antidepressant treatment. In comparison with other studies, the observed rate of severe relapse during 3-year period is rather low. This is one of the first reports demonstrating a beneficial effect of long-term antidepressant medication on severe relapse rates in naturalistic patients. Concomitant antipsychotic medication may be a proxy marker for treatment resistant and psychotic depression.
Similar content being viewed by others
References
Geddes JR, Carney SM, Davies C et al (2003) Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 361:653–661. doi:10.1016/S0140-6736(03)12599-8
Posternak MA, Zimmerman M, Keitner GI, Miller IW (2002) A reevaluation of the exclusion criteria used in antidepressant efficacy trials. Am J Psychiatry 159:191–200
Solomon DA, Leon AC, Endicott J et al (2004) Psychosocial impairment and recurrence of major depression. Compr Psychiatry 45:423–430. doi:10.1016/j.comppsych.2004.07.002
Hughes S, Cohen D (2009) A systematic review of long-term studies of drug treated and non-drug treated depression. J Affect Disord 118:9–18. doi:10.1016/j.jad.2009.01.027
Akanji AO, Ohaeri JU, Al-Shammri SA, Fatania HR (2007) Associations of blood homocysteine concentrations in Arab schizophrenic patients. Clin Biochem 40:1026–1031
Lin C-H, Chen M-C, Chou L-S et al (2010) Time to rehospitalization in patients with major depression vs. those with schizophrenia or bipolar I disorder in a public psychiatric hospital. Psychiatry Res 180:74–79. doi:10.1016/j.psychres.2009.12.003
Lin C-H, Chen Y-S, Lin C-H, Lin K-S (2007) Factors affecting time to rehospitalization for patients with major depressive disorder. Psychiatry Clin Neurosci 61:249–254. doi:10.1111/j.1440-1819.2007.01662.x
Lin C-H, Lin K-S, Lin C-Y et al (2008) Time to rehospitalization in patients with major depressive disorder taking venlafaxine or fluoxetine. J Clin Psychiatry 69:54–59
Lin EH, Katon WJ, VonKorff M et al (1998) Relapse of depression in primary care. Rate and clinical predictors. Arch Fam Med 7:443–449
Berto P, D’Ilario D, Ruffo P et al (2000) Depression: cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ 3:3–10
Seemüller F, Riedel M, Obermeier M et al (2010) Outcomes of 1014 naturalistically treated inpatients with major depressive episode. Eur Neuropsychopharmacol 20:346–355. doi:10.1016/j.euroneuro.2009.11.011
Wittchen HU, Wunderlich U, Gruschwitz S, Zaudig M (1997) Strukturiertes Klinisches Interview für DSM-IV. Hogrefe, Göttingen
Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296
Cording C, Gaebel W, Spengler A (1995) Die neue psychiatrische Basisdokumentation. Eine Empfehlung der DGPPN zur Qualit„tssicherung im (teil-) station„ren Bereich. [The new psychiatric basic documentation. A recommendation by the DGPPN for quality assurance in inpatient treatment]. Spektrum Psychiatr Nervenheilkd 24:3–41
Bauer M, Bschor T, Pfennig A et al (2007) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J Biol Psychiatry 8:67–104
Riedel M, Moller HJ, Obermeier M et al (2010) Response and remission criteria in major depression—a validation of current practice. J Psychiatr Res 44:1063–1068
R Foundation for Statistical Computing (2012) R: a language and environment for statistical computing. Austria, Vienna
Frank E, Prien RF, Jarrett RB et al (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851–855
Akerblad A-C, Bengtsson F, von Knorring L, Ekselius L (2006) Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study. Int Clin Psychopharmacol 21:117–124
Daniels BA, Kirkby KC, Hay DA et al (1998) Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder and depression. Aust N Z J Psychiatry 32:281–286
Leon AC, Solomon DA, Mueller TI et al (2003) A 20-year longitudinal observational study of somatic antidepressant treatment effectiveness. Am J Psychiatry 160:727–733
Copeland JR (1983) Psychotic and neurotic depression: discriminant function analysis and five-year outcome. Psychol Med 13:373–383
Culpepper L (2010) Why do you need to move beyond first-line therapy for major depression? J Clin Psychiatry 71(Suppl 1):4–9. doi:10.4088/JCP.9104su1c.01
Zarate CA Jr, Tohen M (2004) Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 161:169–171
Goodwin G, Fleischhacker W, Arango C et al (2009) Advantages and disadvantages of combination treatment with antipsychotics ECNP consensus meeting, March 2008, Nice. Eur Neuropsychopharmacol 19:520–532. doi:10.1016/j.euroneuro.2009.04.003
Bernardo AC, Forchuk C (2001) Factors associated with readmission to a psychiatric facility. Psychiatr Serv 52:1100–1102
Havassy BE, Hopkin JT (1989) Factors predicting utilization of acute psychiatric inpatient services by frequently hospitalized patients. Hosp Community Psychiatry 40:820–823
Labbate LA, Doyle ME (1997) Recidivism in major depressive disorder. Psychother Psychosom 66:145–149
Solomon DA, Leon AC, Mueller TI et al (2005) Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry 66:283–290
Robinson OJ, Sahakian BJ (2008) Recurrence in major depressive disorder: a neurocognitive perspective. Psychol Med 38:315–318. doi:10.1017/S0033291707001249
Thase ME (2006) Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr 11:12–21
Trivedi MH, Rush AJ, Wisniewski SR et al (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40
Nierenberg AA, Husain MM, Trivedi MH et al (2009) Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 40:1–10
Acknowledgments
The study was performed within the framework of the German Research Network on Depression, which was funded by the German Federal Ministry for Education and Research BMBF (01GI0219). The BMBF had no further role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.
Conflict of interest
All other authors declare that they have no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Seemüller, F., Meier, S., Obermeier, M. et al. Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. Eur Arch Psychiatry Clin Neurosci 264, 567–575 (2014). https://doi.org/10.1007/s00406-014-0495-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00406-014-0495-7